Table 2.
Selected Ongoing Clinical Trials of Novel Agents
| DRUG | MAIN TARGET | CLINICAL TRIAL NUMBER |
|---|---|---|
|
| ||
| RECEPTOR TARGETED THERAPIES | ||
|
| ||
| Brentuximab vedotin (BV) combinations | ||
| Frontline | CD 30+ HRS cells | |
| 1) Phase 3 frontline with AVD versus brentuximab/AVD | 1) NCT01712490 | |
| 2) ECAPPB vs. ECADD B (frontline) | 2) NCT01569204 | |
| Relapsed/Refractory | ||
| 3) ABVD → BV (relapsed) | 3) NCT01578967 | |
| 4) BV+ Bendamustine (relapsed) | 4) NCT01874054 | |
| 5) BV+ Ipilimumab (relapsed) | 5) NCT01896999 | |
| 6) BV vs. ICE pre ASCT (relapsed) | 6) NCT01393717 | |
| 7) BV → ICE (relapsed) | 7) NCT01508312 | |
| 8) BV + Rituximab (relapsed) | 8) NCT01900496 | |
| Maintenance | ||
| 9) BV Maintenance after ASCT (ATHERA) (maintenance) | 9) NCT01620229 | |
|
| ||
| TNX-650 | IL-13 | NCT00441818 |
|
| ||
| MICROENVIRONMENT TARGETING | ||
|
| ||
| Lenalidomide Combinations (relapsed) | ||
| 1) AVD | Immunomodulation, anti-angiogenesis | 1) NCT0105667 |
| 2) Bendamustine, | 2) NCT01412307 | |
| 3) Romidepsin | 3) NCT01742793 | |
| 4) Everolimus | 4) NCT01075321 | |
|
| ||
| Rituximab Combinations | ||
| Frontline | CD20+ peritumoral B lymphocytes; CD20+ HRS cells | |
| 1) Rituximab ABVD vs. ABVD Phase 2 | 1) NCT00654732 | |
| 2) Rituximab + BEACOPP (HD18) | 2) NCT00515554 | |
| Relapsed | ||
| 3) Rituximab + Bendamustine | 3) NCT01900496 | |
|
| ||
| Ipilimumab (relapsed) | Immunomodulation of tumor microenvironment | NCT01896999 |
|
| ||
| Nivolumumaba (relapsed) | PD-1 expressing peritumoral lymphocytes | NCT01592370 |
|
| ||
| CDX1127 (relapsed) | anti-CD27 antibody | NCT0146013 |
|
| ||
| ADOPTIVE IMMUNOTHERAPY | ||
|
| ||
| Autologous CAR.CD30 EBV specific-cytotoxic T-lymphocytes (relapsed) | EBV+ CD30+ HRS cells; CD30+ HRS cells | NCT01192464 |
|
| ||
| DOWNSTREAM SIGNALING PATHWAYS | ||
|
| ||
| MLN4924 (relapsed) | NFκB via inhibition of Ned8 | NCT00722488 |
|
| ||
| Everolimus (relapsed) | PI3K signaling, mTOR, TNFR signaling | |
| 1) Everolimus and Panobinostat | 1) NCT00918333 | |
| 2) Everolimus and Lenalidomide | 2) NCT01075321 | |
Includes patients with HL and NHL;
NR: not reported; NA: not available, ORR: overall response rate; CR: complete response; PR: partial response, PFS: progression free survival; TTP: time to progression; DOR: duration of response; ASCT: autologous stem cell transplant; BV: brentuximab vedotin; AVD: adriamycin, vinblastine, dacarbazine; ECAPP B: brentuximab vedotin in combination with etoposide, cyclophosphamide, adriamcyin, procarbazine, prednisone and brentuximab; ECADD B: etoposide, cyclophosphamide, adriamcyin, doxorubicin, dacarbazine and brentuximab; ABVD: adriamycin, bleomycin, vinblastine, and dacarbazine; BEACOPP: bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone.